Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

Skin Infections, Bacterial Clinical Trial

Official title:
An Open-Label, Non-Comparative Study to Assess the Pharmacokinetics, Safety and Efficacy of Topical Retapamulin (SB-275833) Ointment, 1%, Twice Daily for Five Days in the Treatment of Uncomplicated Skin and Skin Structure Infections in Pediatric Subjects Aged 2 to 24 Months

Status Completed

Clinical Trial Summary

A study to evaluate the pharmacokinetics of Retapamulin Ointment, 1%, in pediatric subjects (2-24 months) with secondarily-infected traumatic lesions, secondarily-infected dermatoses, or impetigo (bullous and non-bullous).

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00555061
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 4
Start date	September 2007
Completion date	August 2008

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01445600` - ALTARGO(Retapamulin) PMS(Post-marketing Surveillance)	N/A
Completed	`NCT00684177` - Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)	Phase 3
Completed	`NCT01153880` - United States Pharmacovigilence Retapamulin-Prescribing	N/A
Completed	`NCT01209078` - GSK1322322 Versus Linezolid in the Treatment of Acute Bacterial Skin and Skin Structure Infection	Phase 2
Completed	`NCT00852540` - Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA	Phase 3
Completed	`NCT00133874` - Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo	Phase 3
Completed	`NCT01812382` - Retapamulin Microdialysis Feasibility Study	Phase 1